Publication in the Journal of the American Academy of Dermatology Describes Phase 2 Clinical Trial Results of CTP 543 for the Treatment of Alopecia Areata

June 7th, 2022

Data were published today in the Journal of the American Academy of Dermatology (JAAD) on the results of Concert Pharmaceuticals’ Phase 2 study with CTP-543 in patients with alopecia areata, an autoimmune disease in which the immune system attacks hair follicles, which results in hair loss and can be associated with a range of physical and psychosocial symptoms. Alopecia areata may affect up to approximately 1.5 million Americans at any given time.

CTP-543 is an investigational oral Janus Kinase (JAK) inhibitor being evaluated in ongoing clinical trials in adults for the treatment of moderate to severe alopecia areata.